FMS earnings

Organic revenue growth1 of 4% with growth in all operating segmentsOperating income2 grew 10%, resulting in further margin expansion to 10.1%FME25+ transformation program related one-time costs mainly drove reported operating income decline of 14% and reported net income3 decrease of 22%Earnings per share2 (EPS) increased by 16%, supported by the share buyback programFY 2026 outlook confirmedBAD HOMBURG, Germany, May 5, 2026 /PRNewswire/ -- "Fresenius Medical Care delivered continued operational and financial progress in the first quarter, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income growth was in line with our planned phasing," said Helen Giz

Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

Strong organic revenue growth1 of 10% driven by all operating segmentsPositive U.S. same market treatment growth of 0.1 % in line with expectationsAccelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7%Reported operating income grew by 3%, reported net income3 by 29%Net leverage ratio further improved to 2.6x, in parallel to share buyback and Value-Based Care investmentsFY 2025 outlook confirmedBAD HOMBURG, Germany, Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlin

Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical

Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care EnablementOperating income1 and operating income margin1 increase driven by Care EnablementAdditional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings target rangeFurther divestitures closed as execution of portfolio optimization program continuesNet financial debt and net leverage ratio further improvedFY 2024 outlook confirmedBAD HOMBURG, Germany, July 30, 2024 /PRNewswire/ -- "In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proo

Solid revenue1 growth of 4% driven by both segments Care Delivery and Care EnablementOperating income1 margin improved in both segments  Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin bandExecution of transformation continues at pace, contributing additional FME25 savings of EUR 52 millionPortfolio optimization program progresses in Care Delivery with signed or closed divestments in all our Latin American markets, and closed divestments in Turkiye and of Cura Day Hospitals Group in AustraliaFY 2024 outlook confirmedBAD HOMBURG, Germany, May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical

Revenue growth of 5% in 2023 driven by favorable business developmentOperating income1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlementSuccessful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care EnablementSeveral key divestments announced as part of the ongoing Portfolio Optimization ProgramStrong cash flow performance and net financial leverage ratio reducedDividend of €1.19 per share proposedFor 2024 continued revenue growth and accelerated operating income growth projectedBAD HOMBURG, Germany, Feb. 20, 2024 /P

Organic growth accelerated in the second quarter in Care Enablement and Care Delivery including sequentially stable treatment volumes in the U.S.Execution on turnaround plan translates into visible productivity improvements in Care Delivery achieving a Q2 margin at the lower end of the 2025 target margin bandSavings resulting from FME25 transformation program fully on trackSuccessful execution on portfolio optimization strategyLegal form conversion to a German Stock Corporation approved by shareholdersFY 2023 operating income guidance range narrowedWALTHAM, Mass., Aug. 2, 2023 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The second quarter makes evide